Q9995 emicizumab-kxwh HCPCS Reimbursement

HCPCS Level II code Q9995 denotes an injection of emicizumab-kxwh, reported per 0.5 mg unit. Emicizumab-kxwh is a targeted monoclonal antibody therapy used in the management of certain bleeding disorders; accurate coding at the unit level is important for clinical documentation and national reimbursement consistency. This code matters nationally because emicizumab therapy involves high-cost biologic dosing that can vary by patient weight and clinical regimen, making standardized unit-based reporting critical for claims processing and utilization monitoring.

Key payers discussed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise review of what HCPCS Level II code Q9995 represents, the typical service setting (outpatient infusion clinic or physician office), and the service type (therapeutic injection). The publication provides benchmarks and policy context relevant to billing and coverage for biologic injectable therapies, outlines typical payer coverage considerations, and highlights areas where coding clarity affects reimbursement and clinical documentation. Data not available in the input will be noted where applicable.

Billing Code Overview

HCPCS Level II code Q9995 represents an injection of emicizumab-kxwh, billed per 0.5 mg unit. This code is used to report administration of emicizumab-kxwh, a monoclonal antibody treatment for bleeding disorders.

Service Type: Therapeutic injection

Typical Site of Service: Outpatient infusion clinic or physician office

Data not available in the input.

Clinical Context

A typical patient is an adult or pediatric individual with hemophilia A with factor VIII inhibitors or severe congenital hemophilia A requiring prophylactic subcutaneous administration of emicizumab-kxwh to reduce bleeding episodes. The clinical workflow begins with a hematology consultation confirming indication and prior authorization with the patient’s insurer. Nursing staff or an infusion clinic educator provides training on subcutaneous injection technique, storage and handling of the product, and a dosing schedule. Each administration visit includes verification of identity, review of recent bleeding events or adverse reactions, confirmation of dose and lot number, preparation of the syringe or vial per product instructions, and observation for 15–30 minutes for immediate hypersensitivity. Documentation includes the HCPCS Level II code Q9995 with the quantity corresponding to 0.5 mg units administered, the date of service, lot number, manufacturer, injection site, and relevant ICD-10 diagnosis code supporting medical necessity. Orders for laboratory monitoring (e.g., inhibitor titers, complete blood count) and periodic follow-up with hematology are typical components of ongoing care.

Coding Specifications

Modifier	Description	When to Use
`GP`	Services delivered under an outpatient physical therapy plan of care	Not applicable to `Q9995` typically; included for outpatient therapy settings when medication administration is part of a therapy visit

Taxonomy Code	Specialty	Notes
`207RH0000X`	Hematology	Hematologists prescribe and manage emicizumab prophylaxis
`363LF0000X`	Infusion Therapy	Infusion nurses or specialty infusion clinic staff administer and document injectable biologics
`165Z00000X`	Nurse Practitioner	Advanced practice providers who manage dosing and follow-up
`207K00000X`	Pediatrics	Pediatric hematology providers manage pediatric hemophilia patients
`208000000X`	Internal Medicine	General internists who co-manage adult patients receiving long-term prophylaxis

Related Diagnoses

ICD-10 Code	Description	Clinical Relevance
`D66`	Hereditary factor VIII deficiency (hemophilia A)	Primary indication for emicizumab prophylaxis in patients with severe hemophilia A
`D68.4`	Acquired coagulation factor deficiency	Relevant when inhibitor development or acquired deficiency prompts alternative prophylactic strategies
`T80.8XXA`	Other complications following infusion, initial encounter	Used if an adverse reaction to a biologic infusion occurs during or after administration
`Z79.01`	Long term (current) use of anticoagulants	May be relevant for medication reconciliation and risk assessment when managing bleeding risk
`Z51.81`	Encounter for therapeutic drug monitoring	Used when patients present for laboratory monitoring related to biologic therapy

Related CPT Codes

CPT Code	Description	Relationship to This Procedure
`96372`	Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular	Commonly billed when documenting the act of subcutaneous administration of `Q9995` if the payer accepts an injection CPT in addition to or instead of HCPCS J/Q code reporting
`36415`	Collection of venous blood by venipuncture	Performed for baseline or monitoring labs such as inhibitor titers or safety labs before or during prophylactic therapy
`96361`	Hydration, intravenous, initial, for infusion, first hour (may be used for IV setup when applicable)	Rarely applicable; included when IV access or infusion setup is part of a combined visit for other concomitant therapies
`99406`	Smoking and tobacco use cessation counseling visit, intermediate, greater than 3 minutes up to 10 minutes	Example of a separately reportable outpatient counseling service that could occur during a clinic visit where `Q9995` is administered
`99001`	Handling and/or administration of drugs requiring special handling (facility-specific, payer-dependent)	Used by some facilities to report specialized handling associated with biologic medications such as emicizumab-kxwh

OpenPayer

Summary & Overview

HCPCS Q9995: Injection of emicizumab-kxwh, 0.5 mg